



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/885,259	02/23/2001	Madhav N. Devalaraja	PC18174A	3713

28880 7590 04/08/2005  
WARNER-LAMBERT COMPANY  
2800 PLYMOUTH RD  
ANN ARBOR, MI 48105

EXAMINER

BELYAVSKYI, MICHAEL A

ART UNIT PAPER NUMBER

1644

DATE MAILED: 04/08/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

09/885,259

Applicant(s)

DEVALARAJA ET AL.

Examiner

Michail A. Belyavskyi

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 22 February 2005.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 34, 36, 48 -52 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 34, 36, 48 -52 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>02/22/05</u> . | 6) <input type="checkbox"/> Other: _____  |

Art Unit: 1644

RESPONSE TO APPLICANT'S AMENDMENT

1. Applicant's amendment, filed 02/22/05 is acknowledged.
2. Claims 34, 36, 48 -52 are pending and under consideration in the instant application.

In view of the amendment, filed 02/22/05 the following rejections remain:

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 34, 36 and 48 -52 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent 5,837,460.

US Patent '460 teaches a method for ameliorating the effects of inflammation including rheumatoid arthritis in a mammal, comprising administering to said mammal a therapeutically effective amount of an M-CSF antigen or antibody to M-CSF antibody wherein M-CSF including human M-CSF (see entire document, Abstract and columns 5 and 9 in particular). US Patent '460 teaches that antibody is monoclonal antibody (see overlapping columns 5 and 6 in particular). In other words, US Patent teaches a method for treating inflammation, including rheumatoid arthritis in a mammal using method of active immunization with M-CSF antigen or anti-antibodies to M-CSF.

Art Unit: 1644

US Patent '460 does not explicitly teaches a method for treating rheumatoid arthritis in a mammal comprising administering to said animal a therapeutically effective amount of antibody to M-CSF .

It is noted that the reference method uses a method of active immunization, while the claimed method uses the method of passive immunization ( administering antibody to a M-CSF) to achieve the same results. It is clear that both the prior art and applicant administer the similar treatment, i.e. active and passive immunization against M-CSF to the same patient to achieve the same results, i.e. to treat rheumatoid arthritis. Therefore it would be obvious to one of ordinary skill in the art at the time the invention was made to substitute active immunization with M-CSF antigen or anti-antibody to M-CSF with passive immunization with antibody M-CSF.

One of ordinary skill in the art at the time the invention was made would have been motivated to do so, because both method of active and passive immunization were well known to one skilled in the art at the time the invention was made. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

5. Claims 34, 36, 48 -52 stand rejected under 35 U.S.C. 103(a) as being unpatentable over WO 00/09561 in view of Campbell et al., (1998, IDS) as is evidence from Campbell et al (2000, IDS) for the same reasons set forth in the Office Action mailed on 11/22/04.

Applicant's arguments filled on 02/22/05 have been fully considered but have not been find convincing.

Applicant asserts that neither references alone or in combination disclosed the limitation of M-CSF.

Contrary to Applicant's assertion it is noted that although Campbell et al., (1998) does not explicitly disclosed M-CSF, it referenced to the general knowledge of one skilled in the art , by citing Metcalt et al and Hamilton et al references. The combined references teach that colony- stimulating factors (CSF) are a family of four cytokine growth factors including macrophage CSF ( M-CSF) and granulocyte-marcophage CSF (GM-CSF) each known to exhibit certain activities that predispose them towards a proinflammatory role *in vivo*. Moreover, the fact that said general knowledge was well known to one skilled in the art at the time the invention was made is evidenced from the second Campbell et al. reference (2000, IDS). In the second reference, Campbell et al., explicitly stated that combined references of Metcalt et a., l (1991) and Hamilton et al (1980) teaches that colony- stimulating factors (CSF) are a family of four cytokine growth factors including macrophage CSF ( M-CSF) and granulocyte-marcophage CSF (GM-CSF) each known to exhibit certain activities that predispose them towards a proinflammatory role *in vivo*. ( see page 144 in particular).

Art Unit: 1644

WO'561 teaches a method for ameliorating the effects of inflammation in a subject including rheumatoid arthritis, comprising administering an antibodies against GM-CSF, ( see entire document, Abstract and overlapping pages 6-7 in particular). WO'561 teaches that). WO'561 teaches that said antibody is monoclonal antibody or humanized antibody ( see page 6 in particular).

WO'561 does not explicitly teach a method for ameliorating the effects of inflammation in a subject including rheumatoid arthritis, comprising administering an antibodies against M-CSF

Campbell et al., teach that colony- stimulating factors (CSF) are a family of four cytokine growth factors including macrophage CSF ( M-CSF) and granulocyte-marcophage CSF (GM-CSF) each known to exhibit certain activities that predispose them towards a proinflammatory role *in vivo*.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to apply the teaching of Campbell et al to those of WO' 561 to obtain a claimed method for treating rheumatoid arthritis in a mammal comprising administering an antibody to a M-CSF

One of ordinary skill in the art at the time the invention was made would have been motivated to do so, because colony- stimulating factors (CSF) are a family of four cytokine growth factors including macrophage CSF ( M-CSF) and granulocyte-marcophage CSF (GM-CSF) each known to exhibit certain activities that predispose them towards a proinflammatory role *in vivo* as taught by Campbell et al. Thus the antibody to one member of the family, i.e. GM-SCF can be substituted with antibody to the other member of the family, i.e. M-CSF in the method of treating rheumatoid arthritis in patients taught by WO 00/09561.

The strongest rationale for combining references is a recognition, expressly or impliedly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal precedent, that some advantage or expected beneficial result would have been produced by their combination. In re Semaker. 217 USPQ 1, 5 - 6 (Fed. Cir. 1983). See MPEP 2144.

From the combined teaching of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Art Unit: 1644

6. No claim is allowed.

7. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskiy whose telephone number is 571/ 272-0840. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571/ 272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michail Belyavskiy, Ph.D.  
Patent Examiner  
Technology Center 1600  
March 30, 2005

  
CHRISTINA CHAN  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600